Publications by authors named "D Bross-Soriano"
Efficacy of cidofovir versus bevacizumab in recurrent respiratory papillomatosis: A randomized, double-blind, placebo-controlled pilot study.
Acta Otorrinolaringol Esp (Engl Ed)
April 2022
Article Synopsis
- This study aimed to compare the effectiveness of two adjuvant therapies, cidofovir and bevacizumab, in controlling recurrent respiratory papillomatosis (RRP) after surgical resection.
- A randomized pilot study involved five children and eleven adults with RRP, who were assigned to receive one of the treatments or a placebo following surgery, with their progress monitored over a year.
- Results indicated that cidofovir led to a significant reduction in RRP severity, but no conclusive effectiveness was found for bevacizumab, and both treatments showed a general improvement in voice quality.
Efficacy of cidofovir versus bevacizumab in recurrent respiratory papillomatosis: A randomized, double-blind, placebo-controlled pilot study.
Acta Otorrinolaringol Esp (Engl Ed)
June 2021
Objectives: After surgical resection of papilloma, adjuvant therapy may be recommended for the control of recurrent respiratory papillomatosis (RRP). As the efficacy of adjuvant therapy remains unproven, the aim of this study was to compare the efficacy of cidofovir versus bevacizumab used as adjuvant therapies for the control of RRP.
Methods: This randomized, double-blind, placebo-controlled pilot study was performed in a national respiratory disease referral centre.
Objective: Respiratory scleroma (RS) is a progressive, chronic, granulomatous disease caused by Klebsiella rhinoscleromatis. There is only one report of RS association with HLA-DQ3. In this study, molecular association of HLA class II and RS was determined.
View Article and Find Full Text PDFJuvenile myofibroma of the neck.
Otolaryngol Head Neck Surg
October 2005
Objective: To review Ludwig's angina medical and surgical approach with small incisions.
Study Design: Retrospective, open, noncomparative, longitudinal.
Methods: All patients with Ludwig's angina who received medical, metabolic, airway management, and surgical treatment from January 1, 1983 to December 31, 2000.